Nanjing Haina Pharmaceutical Technology Co., Ltd. (Haina Pharma) has submitted its listing application to the Hong Kong Stock Exchange (HKEX) Main Board on November 7, with China International Capital Corporation (CICC) acting as the sole sponsor.

According to the prospectus, Haina Pharma operates as an integrated pharmaceutical R&D and manufacturing company, offering CXO services. It also maintains a proprietary product pipeline, primarily commercialized through drug technology transfers.

Per Frost & Sullivan’s report, Haina Pharma ranked second among China’s CXO service providers engaged in drug technology transfers during the track-record period and up to the latest practicable date, based on the total number of approved clinical trials and marketing authorizations. The company also secured the second position in terms of total submitted clinical trial and marketing authorization applications during the same period.